Search
Genmab A/S
GMABAdd to Watchlist
26.535USD
-0.555-2.05%
Market hours （ET）Quotes delayed by 15 min
16.35BMarket Cap
19.99P/E TTM
More Details of Genmab A/S Company
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Genmab A/S Info
Ticker SymbolGMAB
Company nameGenmab A/S
IPO dateOct 01, 2000
CEOVan De Winkel (Jan G.J)
Number of employees2682
Security typeDepository Receipt
Fiscal year-endOct 01
AddressCarl Jacobsens Vej 30
CityVALBY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryDenmark
Postal code2500
Phone4570202728
Websitehttps://www.genmab.com/
Ticker SymbolGMAB
IPO dateOct 01, 2000
CEOVan De Winkel (Jan G.J)
Company Executives of Genmab A/S
Name
Name/Position
Position
Shareholding
Change
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Mr. Rolf K. Hoffmann
Mr. Rolf K. Hoffmann
Independent Director
Independent Director
--
--
Ms. Deirdre P. Connelly
Ms. Deirdre P. Connelly
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Royalties
3.10B
83.39%
Net product sales
398.00M
10.70%
Milestone payments
97.00M
2.61%
Collaboration revenue
70.00M
1.88%
Reimbursement income
53.00M
1.42%
By RegionUSD
Name
Revenue
Proportion
Denmark
3.33B
89.41%
Japan
213.00M
5.73%
U.S.A
180.00M
4.84%
Netherlands
1.00M
0.03%
China
0.00
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Royalties
3.10B
83.39%
Net product sales
398.00M
10.70%
Milestone payments
97.00M
2.61%
Collaboration revenue
70.00M
1.88%
Reimbursement income
53.00M
1.42%
Shareholding Stats
Updated: Thu, Feb 19
Updated: Thu, Feb 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Orbis Investment Management Ltd.
2.35%
AllianceBernstein L.P.
1.77%
Paradigm BioCapital Advisors LP
1.15%
Arrowstreet Capital, Limited Partnership
0.81%
BlackRock Institutional Trust Company, N.A.
0.58%
Other
93.34%
Shareholders
Shareholders
Proportion
Orbis Investment Management Ltd.
2.35%
AllianceBernstein L.P.
1.77%
Paradigm BioCapital Advisors LP
1.15%
Arrowstreet Capital, Limited Partnership
0.81%
BlackRock Institutional Trust Company, N.A.
0.58%
Other
93.34%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
5.75%
Investment Advisor
3.72%
Hedge Fund
2.33%
Research Firm
0.24%
Bank and Trust
0.03%
Pension Fund
0.03%
Family Office
0.02%
Other
87.88%
Institutional Shareholding
Updated: Sun, Apr 5
Updated: Sun, Apr 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
564
74.31M
12.10%
-2.99M
2025Q4
539
65.54M
10.64%
-9.83M
2025Q3
515
64.81M
10.54%
-15.68M
2025Q2
501
65.30M
10.31%
-6.21M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Orbis Investment Management Ltd.
14.42M
2.34%
+3.34M
+30.15%
Dec 31, 2025
AllianceBernstein L.P.
10.88M
1.77%
-76.82K
-0.70%
Dec 31, 2025
Paradigm BioCapital Advisors LP
7.04M
1.14%
+3.22M
+84.44%
Dec 31, 2025
Arrowstreet Capital, Limited Partnership
4.98M
0.81%
+1.33M
+36.64%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
3.58M
0.58%
+976.03K
+37.46%
Dec 31, 2025
Renaissance Technologies LLC
3.49M
0.57%
+671.31K
+23.79%
Dec 31, 2025
Harding Loevner LP
3.37M
0.55%
-114.34K
-3.28%
Dec 31, 2025
Parametric Portfolio Associates LLC
1.69M
0.27%
+109.58K
+6.93%
Dec 31, 2025
First Trust Advisors L.P.
1.34M
0.22%
-352.12K
-20.87%
Dec 31, 2025
Federated Hermes Global Investment Management Corp.
679.38K
0.11%
+256.44K
+60.63%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Tema Oncology ETF
4.2%
First Trust NYSE Arca Biotechnology Index Fund
3.02%
WisdomTree BioRevolution Fund
1.31%
iShares Biotechnology ETF
1.15%
AB Disruptors ETF
0.69%
JPMorgan Healthcare Leaders ETF
0.28%
First Trust NASDAQ BuyWrite Income ETF
0.26%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
ActivePassive International Equity ETF
0.12%
View more
Tema Oncology ETF
Proportion4.2%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.02%
WisdomTree BioRevolution Fund
Proportion1.31%
iShares Biotechnology ETF
Proportion1.15%
AB Disruptors ETF
Proportion0.69%
JPMorgan Healthcare Leaders ETF
Proportion0.28%
First Trust NASDAQ BuyWrite Income ETF
Proportion0.26%
ProShares Ultra Nasdaq Biotechnology
Proportion0.12%
Invesco Nasdaq Biotechnology ETF
Proportion0.12%
ActivePassive International Equity ETF
Proportion0.12%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
